Article info
Short report
Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer
- Correspondence to:
S. Di Palma
Histopathology, Royal Surrey County Hospital, Egerton Road, Guildford, Surrey GU2 7XX, UK; silvana.dipalma{at}royalsurrey.nhs.uk
Citation
Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer
Publication history
- Accepted January 11, 2007
- First published February 9, 2007.
Online issue publication
August 30, 2007
Article Versions
- Previous version (9 February 2007).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2007 Journal of Clinical Pathology